Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

March 11, 2025 Barclays 27th Annual Global Healthcare Conference, Miami Beach, FL Fireside chat: March 12, 2025, from ...

Patients who received cilta-cel had improvements in progression-free survival and overall survival if they had sustained a minimal residual disease-negative complete response or better for at least 1 ...

Novartis is further bolstering its preclinical pipeline and continuing its hunt for a Xolair successor, nailing down a ...

Investors are ramping up AI-related M&A to secure cutting-edge capabilities and market-beating returns, but high valuations and open-source ...

Following the Food and Drug Administration’s approval of Lutathera and Pluvicto in 2018 and 2022, respectively, we predicted ...

TD Cowen 45th Annual Health Care Conference March 3, 2025 9:10 AM ETCompany ParticipantsChris Viehbacher - CEOConference ...

Following positive results from the Phase 1 dose escalation study, BND-22 (SAR444881) is now being tested in Phase 2 trials as monotherapy for patients ...

The PD-1 Inhibitor Drugs Market is expanding due to the rising prevalence of cancer and autoimmune diseases. PD-1 inhibitors, including pembrolizumab, nivolumab, and cemiplimab, play a crucial role in ...

Striking study results last year indicated a new type of medicine may improve on Merck’s dominant immunotherapy, spurring a ...

US oncology-focused Nuvation Bio today announced non-dilutive financings of up to $250 million with Sagard Healthcare ...

BeiGene (ONC) has received FDA approval for Tevimbra for first-line esophageal cancer with chemo. Read more here.